Suppr超能文献

移植根治性肾切除术和移植根治性肾输尿管切除术治疗肾癌:术后和生存结果。

Transplant Radical Nephrectomy and Transplant Radical Nephroureterectomy for Renal Cancer: Postoperative and Survival Outcomes.

机构信息

Department of Urology, Emory University School of Medicine, Atlanta, GA, USA.

School of Medicine, Mercer University, Macon, GA, USA.

出版信息

Ann Transplant. 2020 Oct 23;25:e925865. doi: 10.12659/AOT.925865.

Abstract

BACKGROUND The treatment of complex tumors in non-functioning renal transplants requiring surgical extirpation is challenging. Here, we report the largest series of patients who underwent transplant radical nephrectomy for renal cell carcinoma (RCC) and transplant radical nephroureterectomy for urothelial cell carcinoma (UCC) in their transplanted kidneys. MATERIAL AND METHODS From 2004 to 2018, 10 patients underwent transplant radical nephrectomy (7 patients) and nephroureterectomy (3 patients). Retrospective analyses, in terms of complications, oncological recurrence, and survival, of peri-operative and long-term outcomes, were performed. RESULTS Out of the 10 patients, 7 had RCC and 3 had UCC. No intraoperative mortality occurred. Three patients presented with Clavien-Dindo grade IIIa or greater within 30 days of surgery. Two patients died within 60 days of surgery, both due to vascular events: one due to myocardial infarction and one due to stroke. Two other patients died: one after 2.9 years, due to myocardial infarction, and the other after 6 years, due to unknown reasons. At the 7-year follow-up, there was a 60% overall survival rate. For all patients, average survival post-nephrectomy was approximately 4.5 years, including the 6 living patients and 4 deceased patients. Importantly, there was no observed cancer recurrence. CONCLUSIONS This study reports outcomes of the largest series of transplant radical nephrectomy and nephroureterectomy for malignancies of renal allografts. In the optimized setting, extirpative surgeries appear safe, with favorable long-term oncological and survival outcomes.

摘要

背景

对于需要手术切除的无功能肾移植中复杂肿瘤的治疗具有挑战性。在此,我们报告了最大系列的患者,他们在移植肾脏中接受了肾细胞癌(RCC)的移植根治性肾切除术和尿路上皮细胞癌(UCC)的移植根治性肾输尿管切除术。

材料和方法

2004 年至 2018 年,有 10 名患者接受了移植根治性肾切除术(7 例)和肾输尿管切除术(3 例)。对围手术期和长期结果的并发症、肿瘤复发和生存情况进行了回顾性分析。

结果

10 名患者中,7 名患有 RCC,3 名患有 UCC。无术中死亡。3 名患者在手术后 30 天内出现 Clavien-Dindo 分级 IIIa 或更高。2 名患者在手术后 60 天内死亡,均因血管事件引起:1 例心肌梗死,1 例中风。另外 2 名患者死亡:1 例在 2.9 年后因心肌梗死死亡,另 1 例在 6 年后因不明原因死亡。在 7 年的随访中,总生存率为 60%。对于所有患者,平均肾切除术后生存时间约为 4.5 年,包括 6 名存活患者和 4 名死亡患者。重要的是,没有观察到癌症复发。

结论

本研究报告了最大系列的移植根治性肾切除术和肾移植恶性肿瘤肾输尿管切除术的结果。在优化的环境下,切除手术似乎是安全的,具有良好的长期肿瘤学和生存结果。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c556/7590527/1268a0b81d0f/anntransplant-25-e925865-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验